Actemra claim costs Roche $15K

Roche has been slapped with a fine for breaching the Medicines Australia code of conduct at last year’s ARA meeting in Perth. 

Competitor AbbVie, makers of the biologic adalimumab (Humira), alleged that promotional displays for tocilizumab (Actemra) used during the Australian Rheumatology Association’s Scientific Meeting in Perth last year breached the pharmaceutical industry’s code of conduct.

In an official complaint to Medicine Australia’s Code of Conduct Committee,  AbbVie maintained that Roche’s claim on its conference trade stand: “ACTEMRA